Drug intelligence / Profile preview

Borage seed oil + Echium seed oil

Development stage: Preclinical
Lead developer: Novartis
Administration: Oral

Overview

This combination of oils is used for its anti-inflammatory properties, primarily due to their content of gamma-linolenic acid (GLA) from borage oil and stearidonic acid (SDA) from echium oil. These fatty acids help modify the metabolism of other fatty acids, potentially reducing inflammation by inhibiting leukotriene production, which is beneficial in conditions like asthma[2][3][4]. Borage oil contains GLA, an omega-6 fatty acid, while echium oil contains SDA, an omega-3 fatty acid[1][4].

Other names: Borage and Echium seed oil combination

Targets

LTC4S (Leukotriene C4 synthase)

Beyond the preview

Go deeper on Borage seed oil + Echium seed oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Borage seed oil + Echium seed oil.

Explore the full profile